Publications by authors named "Sahila Mohammed Marunnan"
Background: Deficits in cholinergic neurotransmission due to the degeneration of cholinergic neurons in the brain are believed to be one of the major causes of the memory impairments associated with AD. Targeting acetyl cholinesterase (AChE) surfaced as a potential therapeutic target in the treatment of Alzheimer's disease. The present study is pursued to develop quantitative structure activity relationship (QSAR) models to determine chemical descriptors responsible for AChE activity.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the GABAergic system's role in schizophrenia and seeks herbal compounds as alternatives to current antipsychotics, which have serious side effects.
- - It develops Quantitative Structure-Activity Relationship (QSAR) models using three sets of compounds, including well-known GABA agents like Magnolol and Honokiol, to identify key structural features that impact their biological activity.
- - Results indicate that structural properties such as electronegativity and polarizability are important in enhancing the effectiveness of these herbal compounds as GABA receptor activity modulators.
Unlabelled: The present AChE inhibitors have been successful in the treatment of Alzheimer׳s Diseases however suffers serious side effects. Therefore in this view, the present study was sought to identify compounds with appreciable pharmacological profile targeting AChE. Analogue of Rivastigmine and Fluoxetine hybrid synthesized by Toda et al, 2003 (dataset1), and Coumarin-Tacrine hybrids synthesized by Qi Sun et al (dataset2) formed the test compounds for the present pharmacological evaluation.
View Article and Find Full Text PDFArticle Synopsis
- Current antipsychotic drugs pose risks like severe side effects, prompting research into alternative GABAergic treatments derived from plants for schizophrenia.
- The study evaluates three datasets of plant-based and synthetic compounds for their ability to inhibit GABA (A) receptors, with a focus on the compounds Honokiol and its derivatives.
- Findings indicate that Honokiol and its synthetic derivative (compound 61) have promising drug-like properties, outperforming other tested compounds, and virtual screenings suggest no better alternatives were found among similar compounds.